Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.
Based on the results of the SANDPIPER study in advanced, PIK3CA-mutated breast cancer, Genentech has decided not to advance development of the PI3 kinase inhibitor taselisib.
A new study finds that a shorter treatment course might work just as well as a longer one for women with early-stage HER2-positive breast cancer, NPR says.
Presentations largely reflected negatively on the utility of PD-L1 for stratifying response, but pivotal new data on tumor mutational burden as assessed by Foundation Medicine's genomic sequencing panel.
In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.
